Invasive candidiasis in cancer patients: observations from a randomized clinical trial

被引:39
作者
DiNubile, MJ [1 ]
Hille, D [1 ]
Sable, CA [1 ]
Kartsonis, NA [1 ]
机构
[1] Merck Res Labs, Dept Clin Res, W Point, PA 19486 USA
关键词
candidiasis; cancer; caspofungin; amphotericin B;
D O I
10.1016/j.jinf.2005.01.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background. Invasive candidiasis is a common and serious complication of cancer and its therapy. Methods. We retrospectively identified patients with malignancies enrolled in a double-blind randomized trial of caspofungin (50 mg/day after a 70 mg loading dose) vs. conventional amphotericin B (0.6-1.0 mg/kg/day) as treatment of documented invasive candidiasis. A favorable response required complete resolution of signs and symptoms plus eradication of the Candida pathogen(s). The primary efficacy analysis used a modified intention-to-treat (MITT) approach that included all patients with a confirmed diagnosis of invasive candidiasis who received >= 1 dose of study medication. Results. 74/224 (33%) patients in the MITT population had active malignancies. 25/30 (83%) hematological malignancies were acute or chronic leukaemias. 22/44 (50%) solid tumors were related to the gastrointestinal tract. Patients with hematological malignancies tended to be younger (median [range] age: 49 [19-74] vs. 59 [19-81] years) and have higher baseline acute physiology and chronic health evaluation (APACHE) II scores (mean [range]: 17 [0-28] vs. 15 [5-35]) than patients with solid tumors. Neutropenia [<= 500/mu l] was present on entry in 23 (77%) patients with hematological malignancies and in one (3%) patient with a solid tumor. Candidemia was demonstrated in 56 (88%) cancer patients. C. albicans was the single most frequent isolate in cancer patients, although the majority of cases were caused by non-albicans species. Cancer patients in the caspofungin arm had more hematological malignancies (55 vs. 29%), higher baseline APACHE II scores (> 20 in 36 vs. 15%), more frequent neutropenia (42 vs. 24%), and less C. albicans infections (27 vs. 49%) than the amphotericin B-treated cancer patients. Favorable response rates were 11/18 (61%) and 6/12 (50%) for patents with hematological malignancies treated with caspofungin or amphotericin B, respectively; the corresponding outcomes in patients with solid tumors were 12/15 (80%) and 17/29 (59%) for the 2 treatment arms. 7/14 (50%) aspofungin- and 4/10 (40%) amphotericin B-treated patients who were neutropenic on entry responded favorably. ALL-cause mortality rates during the study for caspofungin recipients were 11/18 (61%) with hematological malignancies and 6/15 (40%) with solid tumors, and for amphotericin recipients were 4/12 (33%) with hematological malignancies and 6/29 (21%) with solid tumors. Conclusions. Underlying cancers, most commonly leukaemias and gastrointestinal tumors, were present in one-third of patients enrolled in this study of invasive candidiasis. Overall, 70% of caspofungin-treated and 56% of amphotericin B-treated cancer patients responded favorably. Response rates were lower for neutropenic leukaemic patients than for non-neutropenic patients with solid tumors in both treatment groups. (c) 2005 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 36 条
[1]   Candidemia in a tertiary care hospital:: Epidemiology and factors influencing mortality [J].
Alonso-Valle, H ;
Acha, O ;
García-Palomo, JD ;
Fariñas-Alvarez, C ;
Fernánez-Mazarrasa, C ;
Fariñas, MC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (04) :254-257
[2]   Predictors of adverse outcome in cancer patients with candidemia [J].
Anaissie, EJ ;
Rex, JH ;
Uzun, Ö ;
Vartivarian, S .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (03) :238-245
[3]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[4]   Subgroup analysis and other (mis)uses of baseline data in clinical trials [J].
Assmann, SF ;
Pocock, SJ ;
Enos, LE ;
Kasten, LE .
LANCET, 2000, 355 (9209) :1064-1069
[5]  
Baran J, 2001, SCAND J INFECT DIS, V33, P137, DOI 10.1080/003655401750065544
[6]   Predictors of adverse outcome from candidal infection in a tertiary care hospital [J].
Ben-Abraham, R ;
Keller, N ;
Teodorovitch, N ;
Barzilai, A ;
Harel, R ;
Barzilay, Z ;
Paret, G .
JOURNAL OF INFECTION, 2004, 49 (04) :317-323
[7]   Estimating attributable mortality of candidemia: Clinical judgement vs. matched cohort studies [J].
Blot, SI ;
Vandewoude, KH .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (02) :132-133
[8]   The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer [J].
Bodey, GP ;
Mardani, M ;
Hanna, HA ;
Boktour, M ;
Abbas, J ;
Girgawy, E ;
Hachem, RY ;
Kontoyiannis, DP ;
Raad, II .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05) :380-385
[9]  
Cui Lu, 2002, J Biopharm Stat, V12, P347, DOI 10.1081/BIP-120014565
[10]  
Deresinski SC, 2003, CLIN INFECT DIS, V36, P1445, DOI 10.1086/375080